Literature DB >> 24840647

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Lola Rahib1, Benjamin D Smith1, Rhonda Aizenberg1, Allison B Rosenzweig1, Julie M Fleshman1, Lynn M Matrisian2.   

Abstract

Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the average annual percentage changes in incidence and death rates. Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common cancers, respectively. Lung cancer is projected to remain the top cancer killer throughout this time period. However, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, respectively. Advances in screening, prevention, and treatment can change cancer incidence and/or death rates, but it will require a concerted effort by the research and healthcare communities now to effect a substantial change for the future. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24840647     DOI: 10.1158/0008-5472.CAN-14-0155

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2000 in total

1.  Wireless, battery-free, flexible, miniaturized dosimeters monitor exposure to solar radiation and to light for phototherapy.

Authors:  Seung Yun Heo; Jeonghyun Kim; Philipp Gutruf; Anthony Banks; Pinghung Wei; Rafal Pielak; Guive Balooch; Yunzhou Shi; Hitoshi Araki; Derrick Rollo; Carey Gaede; Manish Patel; Jean Won Kwak; Amnahir E Peña-Alcántara; Kyu-Tae Lee; Yeojeong Yun; June K Robinson; Shuai Xu; John A Rogers
Journal:  Sci Transl Med       Date:  2018-12-05       Impact factor: 17.956

2.  Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model.

Authors:  Pari V Pandharipande; Curtis Heberle; Emily C Dowling; Chung Yin Kong; Angela Tramontano; Katherine E Perzan; William Brugge; Chin Hur
Journal:  Radiology       Date:  2014-11-12       Impact factor: 11.105

Review 3.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

4.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

5.  NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.

Authors:  Mitali Chattopadhyay; Ravinder Kodela; Gabriela Santiago; Thuy Tien C Le; Niharika Nath; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-02-14       Impact factor: 5.858

Review 6.  Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Authors:  Catherine M Sielaff; Shaker A Mousa
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

7.  KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation.

Authors:  Faraz Bishehsari; Lijuan Zhang; Usman Barlass; Nailliw Z Preite; Sanja Turturro; Matthew S Najor; Brandon B Shetuni; Janet P Zayas; Mahboobeh Mahdavinia; Abde M Abukhdeir; Ali Keshavarzian
Journal:  Int J Cancer       Date:  2018-08-09       Impact factor: 7.396

8.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

Review 9.  [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy].

Authors:  F Gebauer; A I Damanakis; C Bruns
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

10.  Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.

Authors:  Weijing Cai; Ranjala Ratnayake; Michael H Gerber; Qi-Yin Chen; Yichao Yu; Hartmut Derendorf; Jose G Trevino; Hendrik Luesch
Journal:  Invest New Drugs       Date:  2018-08-03       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.